ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive
survivors

J 2021

ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors

HUBACEK, Jaroslav A., Ladislav DUŠEK, Ondřej MÁJEK, Vaclav ADAMEK, Tereza CERVINKOVA et. al.

Basic information

Original name

ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors

Authors

HUBACEK, Jaroslav A. (203 Czech Republic, guarantor), Ladislav DUŠEK (203 Czech Republic, belonging to the institution), Ondřej MÁJEK (203 Czech Republic, belonging to the institution), Vaclav ADAMEK (203 Czech Republic), Tereza CERVINKOVA (203 Czech Republic), Dana DLOUHA (203 Czech Republic) and Vera ADAMKOVA (203 Czech Republic)

Edition

Clinica Chimica Acta, AMSTERDAM, ELSEVIER SCIENCE BV, 2021, 0009-8981

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

20602 Medical laboratory technology ;

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 6.314

RIV identification code

RIV/00216224:14110/21:00121855

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.cca.2021.04.024

UT WoS

000659205000008

Keywords in English

COVID-19; ACE; Polymorphism; Insertion; deletion

Abstract

V originále

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread from China in 2019/ 2020 to all continents. Significant geographical and ethnic differences were described, and host genetic background seems to be important for the resistance to and mortality of COVID-19. Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism (rs4646994) is one of the candidates with the potential to affect infection symptoms and mortality. Methods: In our study, we successfully genotyped 408 SARS-CoV-2-positive COVID-19 survivors (163 asymptomatic and 245 symptomatic) and compared them with a population-based DNA bank of 2,559 subjects. Results: The frequency of ACE I/I homozygotes was significantly increased in COVID-19 patients compared with that in controls (26.2% vs. 21.2%; P = 0.02; OR [95% CI] = 1.55 [1.17-2.05]. Importantly, however, the difference was driven just by the symptomatic subjects (29.0% vs. 21.2% of the I/I homozygotes; P = 0.002; OR [95% CI] = 1.78 [1.22-2.60]). The genotype distribution of the ACE genotypes was almost identical in population controls and asymptomatic SARS-CoV-2-positive patients (P = 0.76). Conclusions: We conclude that ACE I/D polymorphism could have the potential to predict the severity of COVID19, with I/I homozygotes being at increased risk of symptomatic COVID-19.

Citovat

HUBACEK, Jaroslav A., Ladislav DUŠEK, Ondřej MÁJEK, Vaclav ADAMEK, Tereza CERVINKOVA, Dana DLOUHA and Vera ADAMKOVA. ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors. Clinica Chimica Acta. AMSTERDAM: ELSEVIER SCIENCE BV, 2021, vol. 519, AUG 2021, p. 206-209. ISSN 0009-8981. Available from: https://dx.doi.org/10.1016/j.cca.2021.04.024.

@article{1779177,
   author = {Hubacek, Jaroslav A. and Dušek, Ladislav and Májek, Ondřej and Adamek, Vaclav and Cervinkova, Tereza and Dlouha, Dana and Adamkova, Vera},
   article_location = {AMSTERDAM},
   article_number = {AUG 2021},
   doi = {http://dx.doi.org/10.1016/j.cca.2021.04.024},
   keywords = {COVID-19; ACE; Polymorphism; Insertion; deletion},
   language = {eng},
   issn = {0009-8981},
   journal = {Clinica Chimica Acta},
   title = {ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors},
   url = {https://www.sciencedirect.com/science/article/pii/S0009898121001492?via%3Dihub},
   volume = {519},
   year = {2021}
}

TY  - JOUR
ID  - 1779177
AU  - Hubacek, Jaroslav A. - Dušek, Ladislav - Májek, Ondřej - Adamek, Vaclav - Cervinkova, Tereza - Dlouha, Dana - Adamkova, Vera
PY  - 2021
TI  - ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors
JF  - Clinica Chimica Acta
VL  - 519
IS  - AUG 2021
SP  - 206-209
EP  - 206-209
PB  - ELSEVIER SCIENCE BV
SN  - 00098981
KW  - COVID-19
KW  - ACE
KW  - Polymorphism
KW  - Insertion
KW  - deletion
UR  - https://www.sciencedirect.com/science/article/pii/S0009898121001492?via%3Dihub
N2  - Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread from China in 2019/ 2020 to all continents. Significant geographical and ethnic differences were described, and host genetic background seems to be important for the resistance to and mortality of COVID-19. Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism (rs4646994) is one of the candidates with the potential to affect infection symptoms and mortality. Methods: In our study, we successfully genotyped 408 SARS-CoV-2-positive COVID-19 survivors (163 asymptomatic and 245 symptomatic) and compared them with a population-based DNA bank of 2,559 subjects. Results: The frequency of ACE I/I homozygotes was significantly increased in COVID-19 patients compared with that in controls (26.2% vs. 21.2%; P = 0.02; OR [95% CI] = 1.55 [1.17-2.05]. Importantly, however, the difference was driven just by the symptomatic subjects (29.0% vs. 21.2% of the I/I homozygotes; P = 0.002; OR [95% CI] = 1.78 [1.22-2.60]). The genotype distribution of the ACE genotypes was almost identical in population controls and asymptomatic SARS-CoV-2-positive patients (P = 0.76). Conclusions: We conclude that ACE I/D polymorphism could have the potential to predict the severity of COVID19, with I/I homozygotes being at increased risk of symptomatic COVID-19.
ER  -

HUBACEK, Jaroslav A., Ladislav DUŠEK, Ondřej MÁJEK, Vaclav ADAMEK, Tereza CERVINKOVA, Dana DLOUHA and Vera ADAMKOVA. ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors. \textit{Clinica Chimica Acta}. AMSTERDAM: ELSEVIER SCIENCE BV, 2021, vol.~519, AUG 2021, p.~206-209. ISSN~0009-8981. Available from: https://dx.doi.org/10.1016/j.cca.2021.04.024.

Detailed Information on Publication Record